The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Advances in precision-engineered T-cell immunotherapy for alloSCT in AML, ALL and MDS
Samer Srour, MB ChB, MS, The University of Texas MD Anderson Cancer Center, Houston, TX, presents advances in precision-engineered T-cell immunotherapy for allogeneic stem cell transplantation (alloSCT), which aim to reduce graft-versus-host disease (GvHD), infections and non-relapse mortality while preserving the graft-versus-leukemia effect. Dr Srour presents data from the Phase III Precision-T trial (NCT05316701), which led to the FDA approval of ORCA-T in matched donor transplantation for adults with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or myelodysplastic syndromes (MDS). He also discusses the next-generation ORCA-Q (NCT03802695) and a Phase I trial of donor gamma delta T-cells to prevent AML relapse after alloSCT (NCT05015426). This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
